Trodelvy Better Than Chemo at Prolonging Survival in Advanced TNBC, Trial Shows

Trodelvy Better Than Chemo at Prolonging Survival in Advanced TNBC, Trial Shows
Immunomedics has announced that its Phase 3 ASCENT trial of Trodelvy (sacituzumab govitecan) met its main goal of demonstrating that the medication is superior to standard chemotherapy at delaying disease progression and prolonging the survival of people with metastatic triple-negative breast cancer (mTNBC). The biopharmaceutical company had closed ASCENT (NCT02574455) early, in April, due to the strong evidence already gathered of Trodelvy’s ability to halt disease progression in these patients. “The results of the global Phase 3 ASCENT study confirm our initial observations that sacituzumab govitecan has the potential to change the standard management of mTNBC,” Aditya Bardia, MD, MPH, principal investigator of ASCENT, said in a press release. Bardia also is director of precision medicine at the Center for Breast Cancer at the Massachusetts General Hospital Cancer Center<
Subscribe or to access all post and page content.

Pin It on Pinterest

Share This